Loading clinical trials...
Loading clinical trials...
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Conditions
Interventions
(R)-9bMS
Locations
1
United States
University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect
Madison, Wisconsin, United States
Start Date
March 13, 2026
Primary Completion Date
December 30, 2027
Completion Date
March 30, 2028
Last Updated
March 20, 2026
NCT06249750
NCT05828082
NCT04777071
Lead Sponsor
TechnoGenesys, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions